Study Evaluation LXR-623 in Healthy Adults

Healthy Subjects Clinical Trial

Official title:

A Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of LXR-623 Administered Orally to Healthy Subjects

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00379860
• Other study ID #: 3201A1-101
• Status: Terminated
• Phase: Phase 1
• First received: September 21, 2006
• Last updated: March 8, 2007
• Start date: October 2006
• Est. completion date: January 2007

Study information

• Verified date: March 2007
• Source: Wyeth is now a wholly owned subsidiary of Pfizer
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

To evaluate the safety and tolerability of multiple doses of LXR in healthy adults.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 0
• Est. completion date: January 2007
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Generally healthy adults.

• Liver function tests, triglycerideres, and creatinine must be below upper limit of normal at screening.

Exclusion Criteria:

• A history or active presence of clinically important medical disease.

• Any metal implants or devices.

• Claustrophobia.

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Healthy Subjects

Intervention

Drug:
• LXR-623

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Wyeth is now a wholly owned subsidiary of Pfizer

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety is the primary outcome.